European regulators green light new Alzheimer's drug
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
The firm said Biogen partner Eisai’s request for the EMA’s CHMP to reexamine the MAA for lecanemab in amyloid-positive early Alzheimer’s disease has paid off with a positive recommendation that ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback